Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Case Reports in Oncology Année : 2016

Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma

(1) , (2, 3) , , (4) , (5) , , (2, 3)
1
2
3
4
5

Résumé

There is no effective treatment for recurrent glioblastoma (GB) when temozolomide-based radiochemotherapy fails. In theory, intra-arterial (IA) delivery of cytotoxic agents could achieve higher drug concentrations in tumors compared to intravenous injection. Moreover, choosing a highly lipid-soluble drug could make the most of the first-pass effect. Here, we evaluated idarubicin (IDA), a lipophilic anthracycline, in an in vitro assay using four human GB cell lines and compared it with 11 other drugs previously used for the IA treatment of brain tumors. Despite impressive in vitro cytotoxicity, IA IDA did not produce a beneficial effect in 2 patients with recurrent GB. (C) 2016 The Author(s) Published by S. Karger AG, Basel

Dates et versions

hal-03598687 , version 1 (05-03-2022)

Identifiants

Citer

Mohamad Chehimi, Mathieu Boone, Cyril Chivot, Herve Deramond, Jean-Marc Constans, et al.. Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma. Case Reports in Oncology, 2016, 9 (2), pp.499-505. ⟨10.1159/000448654⟩. ⟨hal-03598687⟩
29 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More